CN102471765B9 - 显示出缩短的生物学活性的神经毒素 - Google Patents

显示出缩短的生物学活性的神经毒素 Download PDF

Info

Publication number
CN102471765B9
CN102471765B9 CN201080027593.0A CN201080027593A CN102471765B9 CN 102471765 B9 CN102471765 B9 CN 102471765B9 CN 201080027593 A CN201080027593 A CN 201080027593A CN 102471765 B9 CN102471765 B9 CN 102471765B9
Authority
CN
China
Prior art keywords
polynucleotide
polypeptide
neurotoxin
light chain
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080027593.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102471765B (zh
CN102471765A (zh
Inventor
F·霍夫曼
J·弗雷韦特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Publication of CN102471765A publication Critical patent/CN102471765A/zh
Publication of CN102471765B publication Critical patent/CN102471765B/zh
Application granted granted Critical
Publication of CN102471765B9 publication Critical patent/CN102471765B9/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
CN201080027593.0A 2009-07-02 2010-07-01 显示出缩短的生物学活性的神经毒素 Expired - Fee Related CN102471765B9 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27019809P 2009-07-02 2009-07-02
EP09164365 2009-07-02
EP09164365.0 2009-07-02
US61/270,198 2009-07-02
PCT/EP2010/059398 WO2011000929A1 (en) 2009-07-02 2010-07-01 Neurotoxins exhibiting shortened biological activity

Publications (3)

Publication Number Publication Date
CN102471765A CN102471765A (zh) 2012-05-23
CN102471765B CN102471765B (zh) 2016-05-11
CN102471765B9 true CN102471765B9 (zh) 2016-07-27

Family

ID=40911088

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080027593.0A Expired - Fee Related CN102471765B9 (zh) 2009-07-02 2010-07-01 显示出缩短的生物学活性的神经毒素

Country Status (14)

Country Link
US (4) US8586329B2 (enExample)
EP (1) EP2449101B1 (enExample)
JP (2) JP6059986B2 (enExample)
KR (2) KR101818895B1 (enExample)
CN (1) CN102471765B9 (enExample)
AU (1) AU2010267963B2 (enExample)
BR (1) BRPI1014253A2 (enExample)
CA (1) CA2763692A1 (enExample)
ES (1) ES2693705T3 (enExample)
IL (1) IL216414A (enExample)
IN (1) IN2012DN00733A (enExample)
MX (2) MX2011013014A (enExample)
RU (1) RU2582266C2 (enExample)
WO (1) WO2011000929A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
WO2012125652A2 (en) * 2011-03-14 2012-09-20 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
HK1199890A1 (en) * 2011-11-09 2015-07-24 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
US20150232828A1 (en) 2012-08-20 2015-08-20 Merz Pharma Gmbh & Co. Kgaa Method for the manufacturing of recombinant proteins harbouring an n-terminal lysine
SG11201502032VA (en) 2012-10-16 2015-05-28 Almirall Sa Pyrrolotriazinone derivatives as pi3k inhibitors
RU2673910C2 (ru) 2012-11-21 2018-12-03 Ипсен Байоинновейшн Лимитед Способ производства протеолитически процессированного полипептида
DK2986635T3 (en) 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
ES2642916T3 (es) 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
EP3154572A1 (en) * 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
EP3154635A1 (en) 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
WO2015188943A1 (en) 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Use of recombinant clostridial neurotoxins for the treatment of patients having certain muscle-related disorders
WO2015188944A1 (en) * 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
CN107106780B (zh) 2014-12-23 2020-10-16 莫茨制药有限及两合公司 肉毒杆菌毒素预填充式容器
CN116333068A (zh) 2015-01-09 2023-06-27 益普生生物创新有限公司 阳离子神经毒素
KR102240180B1 (ko) * 2015-03-03 2021-04-14 폰다지오네 텔레톤 다중 벡터 시스템 및 이의 용도
US20180128830A1 (en) * 2015-04-16 2018-05-10 Juliet V. Spencer Detection of human cytomegalovirus in breast cancer
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
KR101793328B1 (ko) * 2015-07-03 2017-11-03 씨제이제일제당 (주) Ｌ-라이신 생산능을 갖는 미생물 및 이를 이용한 ｌ-라이신 생산 방법
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
EP3423084B1 (en) 2016-03-02 2021-09-01 Merz Pharma GmbH & Co. KGaA Composition comprising botulinum toxin
KR102534027B1 (ko) * 2016-06-02 2023-05-18 호유 가부시키가이샤 알 알레르기의 항원
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
TWI871271B (zh) * 2016-11-28 2025-02-01 德商Ｃ 樂克塔股份有限公司 海藻糖磷酸化酶
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
WO2019007509A1 (en) 2017-07-06 2019-01-10 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH INCREASED DURATION
EP3752128B1 (de) * 2018-02-16 2025-01-15 preclinics discovery GmbH Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
CN111868252B (zh) 2018-03-12 2025-06-03 科纳根公司 甜菊糖苷莱苞迪苷j和莱苞迪苷n的生物合成生产
CN117964751A (zh) * 2018-03-13 2024-05-03 斯米维特公司 与破伤风神经毒素结合的单域抗体
US10751399B2 (en) * 2018-03-20 2020-08-25 Cho Pharma Usa, Inc. Chimeric antigen receptors that bind to SSEA4 and uses thereof
CN118956813A (zh) * 2018-05-02 2024-11-15 天野酶制品株式会社 修饰型酯酶和其用途
CN108588087B (zh) * 2018-05-16 2022-06-03 南京农业大学 一种提高植物抗病性的基因GmLecRK-R及其应用
US11535836B2 (en) * 2018-12-21 2022-12-27 Fornia Biosolutions, Inc. Variant G6P G7P glucoamylase compositions and methods
CN109998055B (zh) * 2019-04-09 2022-03-25 黑龙江省科学院大庆分院 一种汉麻籽抗氧化多肽咀嚼片及其制备方法
CN110100945B (zh) * 2019-05-05 2022-05-03 黑龙江省科学院大庆分院 一种汉麻降血脂肽组合物及其应用
CN114391046A (zh) * 2019-06-21 2022-04-22 苏州晶睿生物科技有限公司 一种检测非洲猪瘟病毒的方法和试剂盒
CN110295150A (zh) * 2019-07-17 2019-10-01 天津润德生物科技有限公司 一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
CN110540996B (zh) * 2019-08-29 2022-01-28 华中农业大学 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
CN110643616A (zh) * 2019-10-22 2020-01-03 云南省烟草农业科学研究院 一种烟草降烟碱合成调控基因NtERF91的克隆和应用
JPWO2021167107A1 (enExample) * 2020-02-22 2021-08-26
CN112540178B (zh) * 2020-08-06 2023-12-19 武汉天德生物科技有限公司 一种检测早期老年痴呆症的免疫组化试剂盒及其使用方法
CN112662644B (zh) * 2021-01-19 2022-04-22 华南理工大学 一种甘油磷酸二酯磷酸二酯酶突变体及其应用
CN113899907B (zh) * 2021-09-07 2023-06-27 中国农业科学院油料作物研究所 一步式高效筛选黄曲霉毒素绿色防控材料的方法及其应用
CN115109759B (zh) * 2022-06-24 2024-05-03 浙江工业大学 羰基还原酶LsCR突变体、工程菌及在不对称还原羰基化合物制备手性醇中的应用
CN115944721B (zh) * 2022-12-14 2025-11-25 内蒙古华希生物科技有限公司 一种免疫组合物、其制备方法及应用
CN117741160B (zh) * 2023-12-21 2024-07-12 汉王科技股份有限公司 嗅觉受体在识别乙醇中的用途和检测乙醇的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20060004334A1 (en) 2004-06-30 2006-01-05 Kimberly-Clark Worldwide, Inc. Stabilized absorbent structures
WO2006011966A1 (en) * 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
KR100852824B1 (ko) 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Botulinum neurotoxins: perspective on their existence and as polyproteins harboring viral proteases;DASGUPTA BIBHUTI R;《THE JOURNAL OF GENERAL AND APPLIED MICROBIOLOGY 》;20061231;1－8 *
Modulation of the intracellular stability and toxicity of diphtheria toxin through degradation by the N-end rule pathway;FALNES P O ET AL;《EMBO JOURNAL》;19980101;615－625 *
Modulation of the intracellular stability and toxicity of diphtheria toxin through degradation by the N-end rule pathway;OYLER G A ET AL;《TOXICON》;20080601;17 *

Also Published As

Publication number Publication date
RU2012103376A (ru) 2013-08-10
KR20170016529A (ko) 2017-02-13
US9827298B2 (en) 2017-11-28
RU2582266C2 (ru) 2016-04-20
ES2693705T3 (es) 2018-12-13
CN102471765B (zh) 2016-05-11
JP2012531191A (ja) 2012-12-10
JP2015231378A (ja) 2015-12-24
US20120107362A1 (en) 2012-05-03
EP2449101B1 (en) 2018-10-10
US8586329B2 (en) 2013-11-19
HK1171246A1 (zh) 2013-03-22
EP2449101A1 (en) 2012-05-09
WO2011000929A1 (en) 2011-01-06
MX352265B (es) 2017-11-16
KR20120104140A (ko) 2012-09-20
IL216414A0 (en) 2012-02-29
US9511114B2 (en) 2016-12-06
IN2012DN00733A (enExample) 2015-06-19
BRPI1014253A2 (pt) 2016-04-12
US20160030511A1 (en) 2016-02-04
IL216414A (en) 2016-08-31
MX2011013014A (es) 2012-01-27
US20170072030A1 (en) 2017-03-16
KR101818895B1 (ko) 2018-01-15
US9193771B2 (en) 2015-11-24
AU2010267963A1 (en) 2011-12-22
JP6059986B2 (ja) 2017-01-11
US20140045760A1 (en) 2014-02-13
CN102471765A (zh) 2012-05-23
CA2763692A1 (en) 2011-01-06
AU2010267963B2 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
CN102471765B9 (zh) 显示出缩短的生物学活性的神经毒素
JP6162135B2 (ja) 短縮された生物活性を示す神経毒
RU2673910C2 (ru) Способ производства протеолитически процессированного полипептида
AU2005205597A1 (en) Chimera botulinum toxin type E
US9314514B2 (en) Modified neurotoxins with poly-glycine and uses thereof
HUE033172T2 (en) A method for producing proteolytically processed polypeptides
HK1171246B (en) Neurotoxins exhibiting shortened biological activity
RU2719164C1 (ru) Способы производства протеолитически процессированных полипептидов

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1171246

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C53 Correction of patent of invention or patent application
CI03 Correction of invention patent

Correction item: Nucleotide or amino acid sequence table

False: You

Number: 19

Page: full text

Volume: 32

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1171246

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160511

Termination date: 20190701

CF01 Termination of patent right due to non-payment of annual fee